Siamon Gordon’s research focused on macrophage heterogeneity, differentiation, and activation in mice, and later humans, during development, infection and metabolic disease. His interest in cell fusion led to the development of a range of monoclonal antibodies, which have been widely used to study macrophages intissues such as bone marrow, spleen, and the nervous system. Since 2008, as an Emeritus Professor, he has been immersed in the history of macrophage research —from Ilya Metchnikoff’s pioneering work on the immune system to the discovery of dendritic cells by Ralph Steinman and Zanvil Cohn. The functional significance of macrophage receptors and giant cell formation also remains of interest to him. Dr. Gordon received an honorary doctorate from the University of Cape Town, where he has been involved in the work of the Institute of Infectious Disease and Molecular Medicine for over a decade. During this period, he initiated an AIDS prevention project, publishing an educational cartoon booklet. He is an Honorary Member of the American Association of Immunology and a Fellow of the Academy of Medical Science.

Mark I. Greene received his Doctor of Medicine and Doctor of Philosophy degrees from the University of Manitoba in Canada, and the Federal Rules of Civil Procedure from the Royal College in 1976. In 1976, Dr. Greene moved from Canada to Harvard University. Professor Greene was appointed Assistant Professor at Harvard Medical School in 1978 and then Associate Professor in 1980. Greene was recruited to the University of Pennsylvania in 1986 as Professor of the Center of Receptor Biology.

Dr. Greene was the Newton Abraham Professor of Medical Sciences, Oxford and is currently a trustee of the Abraham Research Trust Unit at the Dunn School and Oxford University. Dr. Greene’s laboratory developed an approach to target and down-modulate oncoproteins which, when expressed, were critical for abnormal growth. This simple approach developed in the neu system involved creating monoclonal antibodies specific for p185. He also developed the use of disabling receptor complexes with two antibodies specific for distinct regions of the receptorproteins. This approach is now approved (Herceptin and Perjeta). The development of a therapy that is useful in resistant tumors provides important insight into why resistance emerges in the first place. Dr. Greene has developed new orally available classes of targeted therapeutics that will function to treat both early and far advanced breast cancer with fewer toxicities.